Where do bright ideas occur in our brain? Meta-analytic evidence from neuroimaging studies of domain-specific creativity

Many studies have assessed the neural underpinnings of creativity, failing to find a clear anatomical localization. We aimed to provide evidence for a multi-componential neural system for creativity. We applied a general activation likelihood estimation (ALE) meta-analysis to 45 fMRI studies. Three individual ALE analyses were performed to assess creativity in different cognitive domains (Musical, Verbal, and Visuo-spatial). The general ALE revealed that creativity relies on clusters of activations in the bilateral occipital, parietal, frontal, and temporal lobes. The individual ALE revealed different maximal activation in different domains. Musical creativity yields activations in the bilateral medial frontal gyrus, in the left cingulate gyrus, middle frontal gyrus, and inferior parietal lobule and in the right postcentral and fusiform gyri. Verbal creativity yields activations mainly located in the left hemisphere, in the prefrontal cortex, middle and superior temporal gyri, inferior parietal lobule, postcentral and supramarginal gyri, middle occipital gyrus, and insula. The right inferior frontal gyrus and the lingual gyrus were also activated. Visuo-spatial creativity activates the right middle and inferior frontal gyri, the bilateral thalamus and the left precentral gyrus. This evidence suggests that creativity relies on multi-componential neural networks and that different creativity domains depend on different brain regions

Optimal Control Problems with Mixed and Pure State Constraints

This paper provides necessary conditions of optimality for optimal control problems, in which the pathwise constraints comprise both “pure” constraints on the state variable and “mixed” constraints on control and state variables. The proofs are along the lines of earlier analysis for mixed constraint problems, according to which Clarke's theory of “stratified” necessary conditions is applied to a modified optimal control problem resulting from absorbing the mixed constraint into the dynamics; the difference here is that necessary conditions which now take into account the presence of pure state constraints are applied to the modified problem. Necessary conditions are given for a rather general formulation of the problem containing both forms of the constraints, and then these are specialized to problems having special structure. While combined pure state and mixed control/state problems have been previously treated in the literature, the necessary conditions in this paper are proved under less restrictive hypotheses and for novel formulations of the constraints

Front-end Electronics Test for the LHCb Muon Wire Chambers

This document describes the apparatus and procedures implemented to test Multi Wire Proportional Chambers (MWPC) after front-end assembly for the LHCb Muon Detector. Results of measurements of key noise parameters are also described. Given a fully equipped chamber, this system is able to diagnose every channel performing an analysis of front-end output drivers’ response and noise rate versus threshold. Besides, it allows to assess if the noise rate at the experiment threshold region is within appropriate limits. Aiming at an automatic, fast and user-friendly system for mass production tests of MWPC, the project has foreseen as well electronic identification of every chamber and front-end board, and data archiving in such a way to make it available to the Experiment Control System (ECS) while in operation

Public Health Genomics: moving towards the implementation of dedicated policies in Europe

n/

El art. 37 de la Constitución Provincial, la ley 20.705 y las sociedades del Estado creadas en el ámbito provincial.

Para una mejor ubicación del tema en estudio es conveniente destacar que la problemática jurídica implicada encuadra en las nor- mas y principios del Derecho Público Provincial

Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial

PURPOSE: Subcutaneous APF530 provides controlled sustained release of granisetron to prevent acute (0-24 h) and delayed (24-120 h) chemotherapy-induced nausea and vomiting (CINV). This randomized, double-blind phase 3 trial compared APF530 and palonosetron in preventing acute and delayed CINV after moderately (MEC) or highly emetogenic chemotherapy (HEC). METHODS: Patients receiving single-day MEC or HEC received single-dose APF530 250 or 500 mg subcutaneously (SC) (granisetron 5 or 10 mg) or intravenous palonosetron 0.25 mg. Primary objectives were to establish APF530 noninferiority to palonosetron for preventing acute CINV following MEC or HEC and delayed CINV following MEC and to determine APF530 superiority to palonosetron for preventing delayed CINV following HEC. The primary efficacy end point was complete response (CR [using CI difference for APF530 - palonosetron]). A lower confidence bound greater than -15 % indicated noninferiority. RESULTS: In the modified intent-to-treat population (MEC = 634; HEC = 707), both APF530 doses were noninferior to palonosetron in preventing acute CINV after MEC (CRs 74.8 % [-9.8, 9.3] and 76.9 % [-7.5, 11.4], respectively, vs. 75.0 % palonosetron) and after HEC (CRs 77.7 % [-11.5, 5.5] and 81.3 % [-7.7, 8.7], respectively, vs. 80.7 % palonosetron). APF530 500 mg was noninferior to palonosetron in preventing delayed CINV after MEC (CR 58.5 % [-9.5, 12.1] vs. 57.2 % palonosetron) but not superior in preventing delayed CINV after HEC. Adverse events were generally mild and unrelated to treatment, the most common (excluding injection-site reactions) being constipation. CONCLUSIONS: A single subcutaneous APF530 injection offers a convenient alternative to palonosetron for preventing acute and delayed CINV after MEC or HEC